At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 35 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML)
In Brief
A Phase 1 clinical trial evaluating Dasatinib and Nivolumab for Chronic Myeloid Leukemia. Completed, enrolled 35 participants across 21 sites in 7 countries.
Detailed Summary
The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myeloid Leukemia
CountriesAustralia, Canada, France, Germany, Italy, Spain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartFeb 2014
Primary CompletionDec 2018
TodayJul 2026
First PostedDec 16, 2013
Enrollment StartFeb 7, 2014
Primary CompletionDec 26, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 12.5 years ago
Interventions
Dasatinibdrug
Nivolumabdrug